Quest Diagnostics (DGX) Tops Q2 EPS by 2c; beats on guidance

Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $2.30, $0.02 better than the analyst estimate of $2.28. Revenue for the quarter came in at $2.34 billion versus the consensus estimate of $2.25 billion.

GUIDANCE:

Quest Diagnostics sees FY2023 EPS of $8.50-$8.90, versus the consensus of $8.69. Quest Diagnostics sees FY2023 revenue of $9.12-9.22 billion, versus the consensus of $9.06 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• Redburn upgrades Southwest, stays bullish on Delta and United